ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1173

Targeting Remission in Juvenile Idiopathic Arthritis in Routine Clinical Care: Experience in 175 Newly-Diagnosed Patients

Alessandro Consolaro1, Giorgia Negro1, Nicoletta Solari1, Cristina Ferrari1, Sergio Davì1, Silvia Pederzoli1, Giulia Bracciolini1, Maria C. Gallo1, Alberto Martini2 and Angelo Ravelli3, 1Pediatria II, Istituto Giannina Gaslini, Genova, Italy, 2Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 3Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: juvenile idiopathic arthritis (JIA), outcome measures and treatment options

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The recent advances in the management of juvenile idiopathic arthritis (JIA) have increased considerably the potential to achieve disease remission or, at least, low levels of disease activity, and have consequently moved the therapeutic aims increasingly towards the attainment of an inactive disease (ID) status. Complete disease quiescence is regarded as the ideal therapeutic target because its achievement helps preventing further joint damage and disability and may enhance physical function and quality of life. These issues have led to suggest that a tight control approach be adopted in the management of children with JIA. We describe our experience with treating JIA patients to specified targets.

Methods: Starting in March 2007, a treat-to-target approach to the management of all children with JIA first seen in the senior author’s clinic was implemented, setting achievement of  ID as primary goal and achievement of minimal disease activity (MDA) or parent-acceptable symptom state (PASS) as secondary goal. In case primary goal was not reached, treatment was intensified as deemed necessary. For the purpose of this study, patient records were reviewed to evaluate the frequency of achievement of primary and secondary therapeutic goals at 6, 12, 18 and 24 months following initial evaluation. ID, MDA and PASS were defined according to both established criteria and Juvenile Arthritis Disease Activity Score (JADAS) cutoffs. The outcome of patients who achieved or did not achieve ID at last follow-up visit was compared by means of the Juvenile Arthritis Functionality Scale (JAFS) and the Pediatric Rheumatology Quality of Life scale (PRQL).

Results: A total of 175 patients (77.7% females) were enrolled. The most common ILAR subtypes were persistent oligoarthritis (53.1%), extended oligoarthritis (14.9%), and RF-negative polyarthritis (14.3%); 3.4% of patients had systemic arthritis. The median age at disease onset was 2.8 years. At baseline visit, the median age was 3.5 years and the median disease duration was 0.2 years. Initial therapeutic interventions included intra-articular corticosteroid injection (84%), methotrexate (28%), systemic corticosteroids (5.7%), and biologic medications (1.1%). The frequency of achievement of treatment goals at study endpoints is shown in the table. At last follow-up visit, patients who had achieved ID had better functional ability (p=0.007) and physical well-being (p=0.007) than those who did not. The frequency of clinical remission on medication was 29.2%.

 

6 months
N (%)

12 months
N (%)

18 months
N (%)

24 months
N (%)

Inactive disease (ID)

50 (35.2)

48 (41)

46 (47.4)

45 (50.6)

Minimal disease activity (MDA)

62 (43.7)

71 (60.7)

60 (61.9)

53 (59.6)

Parent-acceptable symptom state(PASS)

76 (66.1)

77 (74.8)

69 (82.1)

53 (70.7)

JADAS10 ≤ 1 (ID)

43 (31.6)

46 (41.4)

43 (46.2)

33 (39.3)

JADAS10 ≤ 2/3.8 (MDA)

51 (37.5)

58 (52.3)

60 (64.5)

40 (47.6)

JADAS10 ≤ 3.5/5.4 (PASS)

64 (47.1)

66 (59.5)

67 (72)

52 (61.9)

Conclusion: At 2 years after initial visit, a substantial percentage of patients had reached the states of ID or MDA or were in PASS. Patients who achieved ID had better physical function and well-being than those who did not. These findings suggest that the implementation of a treat-to-target approach may help improve patient outcomes.


Disclosure:

A. Consolaro,
None;

G. Negro,
None;

N. Solari,
None;

C. Ferrari,
None;

S. Davì,
None;

S. Pederzoli,
None;

G. Bracciolini,
None;

M. C. Gallo,
None;

A. Martini,
None;

A. Ravelli,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-remission-in-juvenile-idiopathic-arthritis-in-routine-clinical-care-experience-in-175-newly-diagnosed-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology